The sodium-glucose co-transporter 2 inhibitor empagliflozin improves diabetes-induced vascular dysfunction in the streptozotocin diabetes rat model by interfering with oxidative stress and glucotoxicity
In diabetes, vascular dysfunction is characterized by impaired endothelial function due to increased oxidative stress. Empagliflozin, as a selective sodium-glucose co-transporter 2 inhibitor (SGLT2i), offers a novel approach for the treatment of type 2 diabetes by enhancing urinary glucose excretion...
Gespeichert in:
| Veröffentlicht in: | PloS one 2014-11, Vol.9 (11), p.e112394-e112394 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | e112394 |
|---|---|
| container_issue | 11 |
| container_start_page | e112394 |
| container_title | PloS one |
| container_volume | 9 |
| creator | Oelze, Matthias Kröller-Schön, Swenja Welschof, Philipp Jansen, Thomas Hausding, Michael Mikhed, Yuliya Stamm, Paul Mader, Michael Zinßius, Elena Agdauletova, Saule Gottschlich, Anna Steven, Sebastian Schulz, Eberhard Bottari, Serge P Mayoux, Eric Münzel, Thomas Daiber, Andreas |
| description | In diabetes, vascular dysfunction is characterized by impaired endothelial function due to increased oxidative stress. Empagliflozin, as a selective sodium-glucose co-transporter 2 inhibitor (SGLT2i), offers a novel approach for the treatment of type 2 diabetes by enhancing urinary glucose excretion. The aim of the present study was to test whether treatment with empagliflozin improves endothelial dysfunction in type I diabetic rats via reduction of glucotoxicity and associated vascular oxidative stress.
Type I diabetes in Wistar rats was induced by an intravenous injection of streptozotocin (60 mg/kg). One week after injection empagliflozin (10 and 30 mg/kg/d) was administered via drinking water for 7 weeks. Vascular function was assessed by isometric tension recording, oxidative stress parameters by chemiluminescence and fluorescence techniques, protein expression by Western blot, mRNA expression by RT-PCR, and islet function by insulin ELISA in serum and immunohistochemical staining of pancreatic tissue. Advanced glycation end products (AGE) signaling was assessed by dot blot analysis and mRNA expression of the AGE-receptor (RAGE).
Treatment with empagliflozin reduced blood glucose levels, normalized endothelial function (aortic rings) and reduced oxidative stress in aortic vessels (dihydroethidium staining) and in blood (phorbol ester/zymosan A-stimulated chemiluminescence) of diabetic rats. Additionally, the pro-inflammatory phenotype and glucotoxicity (AGE/RAGE signaling) in diabetic animals was reversed by SGLT2i therapy.
Empagliflozin improves hyperglycemia and prevents the development of endothelial dysfunction, reduces oxidative stress and improves the metabolic situation in type 1 diabetic rats. These preclinical observations illustrate the therapeutic potential of this new class of antidiabetic drugs. |
| doi_str_mv | 10.1371/journal.pone.0112394 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_plos_</sourceid><recordid>TN_cdi_plos_journals_1625577213</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A418424611</galeid><doaj_id>oai_doaj_org_article_89298fb08472410b8081d15236c79a94</doaj_id><sourcerecordid>A418424611</sourcerecordid><originalsourceid>FETCH-LOGICAL-c762t-1b0cfbc8c5f4ef94b6a36e5ddc46891958451c7bd83bc9ba355b32edcfed8d423</originalsourceid><addsrcrecordid>eNqNk11rFDEUhgdRbK3-A9GAIHox6-Rjvm6EUvwoFApavQ2Z5MxsSiYZk8za7U_0V5ntbktXeiHDMMPJ877nJCcny17iYoFpjT9cutlbYRaTs7AoMCa0ZY-yQ9xSklekoI_v_R9kz0K4LIqSNlX1NDsgJSsIqcvD7M_FElBwSs9jPphZugBIujx6YcPkfASPCNJ2qTsdnUcwTmIwujfuWlukx8m7FQSktOggQsi1VbMEhVYiyNkIj9Q69LOVUbuEWxQ32aKHKbprF51MoVst8iKi0SkwqFsnNqXuwWs7oN86LpG70kpEvdrqQ0DCKnRTcUxLUsf18-xJL0yAF7vvUfbj86eLk6_52fmX05Pjs1zWFYk57grZd7KRZc-gb1lXCVpBqZRkVdPitmxYiWXdqYZ2su0ELcuOElCyB9UoRuhR9nrrOxkX-K4NgeOKlGVdE0wTcbollBOXfPJ6FH7NndD8JuD8wIWPWhrgTUvapu-KhtWE4aJrigYrXBJayboVLUteH3fZ5m5MVYBNvTF7pvsrVi_54FY8VcpoVSeDdzsD737NECIfdZBgjLDg5pu6q_RSukHf_IM-vLsdNYi0AW17l_LKjSk_ZrhhhFUYJ2rxAJUeBaOW6c72OsX3BO_3BImJcBUHMYfAT79_-3_2_Oc--_YeuwRh4jI4M2-uZNgH2RaU3oXgob87ZFzwzcjdngbfjBzfjVySvbrfoDvR7YzRv0lyLRI</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1625577213</pqid></control><display><type>article</type><title>The sodium-glucose co-transporter 2 inhibitor empagliflozin improves diabetes-induced vascular dysfunction in the streptozotocin diabetes rat model by interfering with oxidative stress and glucotoxicity</title><source>MEDLINE</source><source>DOAJ Directory of Open Access Journals</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><source>Free Full-Text Journals in Chemistry</source><source>Public Library of Science (PLoS)</source><creator>Oelze, Matthias ; Kröller-Schön, Swenja ; Welschof, Philipp ; Jansen, Thomas ; Hausding, Michael ; Mikhed, Yuliya ; Stamm, Paul ; Mader, Michael ; Zinßius, Elena ; Agdauletova, Saule ; Gottschlich, Anna ; Steven, Sebastian ; Schulz, Eberhard ; Bottari, Serge P ; Mayoux, Eric ; Münzel, Thomas ; Daiber, Andreas</creator><creatorcontrib>Oelze, Matthias ; Kröller-Schön, Swenja ; Welschof, Philipp ; Jansen, Thomas ; Hausding, Michael ; Mikhed, Yuliya ; Stamm, Paul ; Mader, Michael ; Zinßius, Elena ; Agdauletova, Saule ; Gottschlich, Anna ; Steven, Sebastian ; Schulz, Eberhard ; Bottari, Serge P ; Mayoux, Eric ; Münzel, Thomas ; Daiber, Andreas</creatorcontrib><description>In diabetes, vascular dysfunction is characterized by impaired endothelial function due to increased oxidative stress. Empagliflozin, as a selective sodium-glucose co-transporter 2 inhibitor (SGLT2i), offers a novel approach for the treatment of type 2 diabetes by enhancing urinary glucose excretion. The aim of the present study was to test whether treatment with empagliflozin improves endothelial dysfunction in type I diabetic rats via reduction of glucotoxicity and associated vascular oxidative stress.
Type I diabetes in Wistar rats was induced by an intravenous injection of streptozotocin (60 mg/kg). One week after injection empagliflozin (10 and 30 mg/kg/d) was administered via drinking water for 7 weeks. Vascular function was assessed by isometric tension recording, oxidative stress parameters by chemiluminescence and fluorescence techniques, protein expression by Western blot, mRNA expression by RT-PCR, and islet function by insulin ELISA in serum and immunohistochemical staining of pancreatic tissue. Advanced glycation end products (AGE) signaling was assessed by dot blot analysis and mRNA expression of the AGE-receptor (RAGE).
Treatment with empagliflozin reduced blood glucose levels, normalized endothelial function (aortic rings) and reduced oxidative stress in aortic vessels (dihydroethidium staining) and in blood (phorbol ester/zymosan A-stimulated chemiluminescence) of diabetic rats. Additionally, the pro-inflammatory phenotype and glucotoxicity (AGE/RAGE signaling) in diabetic animals was reversed by SGLT2i therapy.
Empagliflozin improves hyperglycemia and prevents the development of endothelial dysfunction, reduces oxidative stress and improves the metabolic situation in type 1 diabetic rats. These preclinical observations illustrate the therapeutic potential of this new class of antidiabetic drugs.</description><identifier>ISSN: 1932-6203</identifier><identifier>EISSN: 1932-6203</identifier><identifier>DOI: 10.1371/journal.pone.0112394</identifier><identifier>PMID: 25402275</identifier><language>eng</language><publisher>United States: Public Library of Science</publisher><subject>Advanced glycosylation end products ; Age ; Animals ; Antidiabetics ; Aorta ; Benzhydryl Compounds - administration & dosage ; Benzhydryl Compounds - pharmacology ; Blood ; Blood glucose ; Blood Glucose - drug effects ; Blood vessels ; Cardiology ; Chemiluminescence ; Cytokines - genetics ; Cytokines - metabolism ; Dehydrogenases ; Diabetes ; Diabetes Complications - drug therapy ; Diabetes Complications - metabolism ; Diabetes mellitus ; Diabetes Mellitus, Experimental ; Diabetes therapy ; Diabetic Angiopathies - drug therapy ; Diabetic Angiopathies - metabolism ; Diabetic neuropathy ; Drinking water ; Drugs ; Enzyme-linked immunosorbent assay ; Excretion ; Fluorescence ; Gene Expression ; Glucose ; Glucose - metabolism ; Glucose transporter ; Glucosides - administration & dosage ; Glucosides - pharmacology ; Glycosylation ; Health aspects ; Hemodynamics - drug effects ; Hyperglycemia ; Hypoglycemic agents ; Inflammation ; Inflammation Mediators - metabolism ; Inhibitors ; Injection ; Insulin ; Insulin - blood ; Insulin - metabolism ; Intravenous administration ; Isometric ; Laboratory animals ; Male ; Medicine and Health Sciences ; Oxidation ; Oxidative stress ; Oxidative Stress - drug effects ; Pancreas ; Polymerase chain reaction ; Rats ; Receptor for Advanced Glycation End Products ; Receptors, Immunologic - metabolism ; RNA ; RNA, Messenger - genetics ; Rodents ; Signal Transduction ; Signaling ; Sodium ; Sodium-Glucose Transporter 2 - antagonists & inhibitors ; Staining ; Streptozocin ; Streptozocin - adverse effects ; Studies ; Type 1 diabetes ; Type 2 diabetes</subject><ispartof>PloS one, 2014-11, Vol.9 (11), p.e112394-e112394</ispartof><rights>COPYRIGHT 2014 Public Library of Science</rights><rights>2014 Oelze et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License: http://creativecommons.org/licenses/by/4.0/ (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2014 Oelze et al 2014 Oelze et al</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c762t-1b0cfbc8c5f4ef94b6a36e5ddc46891958451c7bd83bc9ba355b32edcfed8d423</citedby><cites>FETCH-LOGICAL-c762t-1b0cfbc8c5f4ef94b6a36e5ddc46891958451c7bd83bc9ba355b32edcfed8d423</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4234367/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4234367/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,860,881,2096,2915,23845,27901,27902,53766,53768,79342,79343</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/25402275$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Oelze, Matthias</creatorcontrib><creatorcontrib>Kröller-Schön, Swenja</creatorcontrib><creatorcontrib>Welschof, Philipp</creatorcontrib><creatorcontrib>Jansen, Thomas</creatorcontrib><creatorcontrib>Hausding, Michael</creatorcontrib><creatorcontrib>Mikhed, Yuliya</creatorcontrib><creatorcontrib>Stamm, Paul</creatorcontrib><creatorcontrib>Mader, Michael</creatorcontrib><creatorcontrib>Zinßius, Elena</creatorcontrib><creatorcontrib>Agdauletova, Saule</creatorcontrib><creatorcontrib>Gottschlich, Anna</creatorcontrib><creatorcontrib>Steven, Sebastian</creatorcontrib><creatorcontrib>Schulz, Eberhard</creatorcontrib><creatorcontrib>Bottari, Serge P</creatorcontrib><creatorcontrib>Mayoux, Eric</creatorcontrib><creatorcontrib>Münzel, Thomas</creatorcontrib><creatorcontrib>Daiber, Andreas</creatorcontrib><title>The sodium-glucose co-transporter 2 inhibitor empagliflozin improves diabetes-induced vascular dysfunction in the streptozotocin diabetes rat model by interfering with oxidative stress and glucotoxicity</title><title>PloS one</title><addtitle>PLoS One</addtitle><description>In diabetes, vascular dysfunction is characterized by impaired endothelial function due to increased oxidative stress. Empagliflozin, as a selective sodium-glucose co-transporter 2 inhibitor (SGLT2i), offers a novel approach for the treatment of type 2 diabetes by enhancing urinary glucose excretion. The aim of the present study was to test whether treatment with empagliflozin improves endothelial dysfunction in type I diabetic rats via reduction of glucotoxicity and associated vascular oxidative stress.
Type I diabetes in Wistar rats was induced by an intravenous injection of streptozotocin (60 mg/kg). One week after injection empagliflozin (10 and 30 mg/kg/d) was administered via drinking water for 7 weeks. Vascular function was assessed by isometric tension recording, oxidative stress parameters by chemiluminescence and fluorescence techniques, protein expression by Western blot, mRNA expression by RT-PCR, and islet function by insulin ELISA in serum and immunohistochemical staining of pancreatic tissue. Advanced glycation end products (AGE) signaling was assessed by dot blot analysis and mRNA expression of the AGE-receptor (RAGE).
Treatment with empagliflozin reduced blood glucose levels, normalized endothelial function (aortic rings) and reduced oxidative stress in aortic vessels (dihydroethidium staining) and in blood (phorbol ester/zymosan A-stimulated chemiluminescence) of diabetic rats. Additionally, the pro-inflammatory phenotype and glucotoxicity (AGE/RAGE signaling) in diabetic animals was reversed by SGLT2i therapy.
Empagliflozin improves hyperglycemia and prevents the development of endothelial dysfunction, reduces oxidative stress and improves the metabolic situation in type 1 diabetic rats. These preclinical observations illustrate the therapeutic potential of this new class of antidiabetic drugs.</description><subject>Advanced glycosylation end products</subject><subject>Age</subject><subject>Animals</subject><subject>Antidiabetics</subject><subject>Aorta</subject><subject>Benzhydryl Compounds - administration & dosage</subject><subject>Benzhydryl Compounds - pharmacology</subject><subject>Blood</subject><subject>Blood glucose</subject><subject>Blood Glucose - drug effects</subject><subject>Blood vessels</subject><subject>Cardiology</subject><subject>Chemiluminescence</subject><subject>Cytokines - genetics</subject><subject>Cytokines - metabolism</subject><subject>Dehydrogenases</subject><subject>Diabetes</subject><subject>Diabetes Complications - drug therapy</subject><subject>Diabetes Complications - metabolism</subject><subject>Diabetes mellitus</subject><subject>Diabetes Mellitus, Experimental</subject><subject>Diabetes therapy</subject><subject>Diabetic Angiopathies - drug therapy</subject><subject>Diabetic Angiopathies - metabolism</subject><subject>Diabetic neuropathy</subject><subject>Drinking water</subject><subject>Drugs</subject><subject>Enzyme-linked immunosorbent assay</subject><subject>Excretion</subject><subject>Fluorescence</subject><subject>Gene Expression</subject><subject>Glucose</subject><subject>Glucose - metabolism</subject><subject>Glucose transporter</subject><subject>Glucosides - administration & dosage</subject><subject>Glucosides - pharmacology</subject><subject>Glycosylation</subject><subject>Health aspects</subject><subject>Hemodynamics - drug effects</subject><subject>Hyperglycemia</subject><subject>Hypoglycemic agents</subject><subject>Inflammation</subject><subject>Inflammation Mediators - metabolism</subject><subject>Inhibitors</subject><subject>Injection</subject><subject>Insulin</subject><subject>Insulin - blood</subject><subject>Insulin - metabolism</subject><subject>Intravenous administration</subject><subject>Isometric</subject><subject>Laboratory animals</subject><subject>Male</subject><subject>Medicine and Health Sciences</subject><subject>Oxidation</subject><subject>Oxidative stress</subject><subject>Oxidative Stress - drug effects</subject><subject>Pancreas</subject><subject>Polymerase chain reaction</subject><subject>Rats</subject><subject>Receptor for Advanced Glycation End Products</subject><subject>Receptors, Immunologic - metabolism</subject><subject>RNA</subject><subject>RNA, Messenger - genetics</subject><subject>Rodents</subject><subject>Signal Transduction</subject><subject>Signaling</subject><subject>Sodium</subject><subject>Sodium-Glucose Transporter 2 - antagonists & inhibitors</subject><subject>Staining</subject><subject>Streptozocin</subject><subject>Streptozocin - adverse effects</subject><subject>Studies</subject><subject>Type 1 diabetes</subject><subject>Type 2 diabetes</subject><issn>1932-6203</issn><issn>1932-6203</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><sourceid>DOA</sourceid><recordid>eNqNk11rFDEUhgdRbK3-A9GAIHox6-Rjvm6EUvwoFApavQ2Z5MxsSiYZk8za7U_0V5ntbktXeiHDMMPJ877nJCcny17iYoFpjT9cutlbYRaTs7AoMCa0ZY-yQ9xSklekoI_v_R9kz0K4LIqSNlX1NDsgJSsIqcvD7M_FElBwSs9jPphZugBIujx6YcPkfASPCNJ2qTsdnUcwTmIwujfuWlukx8m7FQSktOggQsi1VbMEhVYiyNkIj9Q69LOVUbuEWxQ32aKHKbprF51MoVst8iKi0SkwqFsnNqXuwWs7oN86LpG70kpEvdrqQ0DCKnRTcUxLUsf18-xJL0yAF7vvUfbj86eLk6_52fmX05Pjs1zWFYk57grZd7KRZc-gb1lXCVpBqZRkVdPitmxYiWXdqYZ2su0ELcuOElCyB9UoRuhR9nrrOxkX-K4NgeOKlGVdE0wTcbollBOXfPJ6FH7NndD8JuD8wIWPWhrgTUvapu-KhtWE4aJrigYrXBJayboVLUteH3fZ5m5MVYBNvTF7pvsrVi_54FY8VcpoVSeDdzsD737NECIfdZBgjLDg5pu6q_RSukHf_IM-vLsdNYi0AW17l_LKjSk_ZrhhhFUYJ2rxAJUeBaOW6c72OsX3BO_3BImJcBUHMYfAT79_-3_2_Oc--_YeuwRh4jI4M2-uZNgH2RaU3oXgob87ZFzwzcjdngbfjBzfjVySvbrfoDvR7YzRv0lyLRI</recordid><startdate>20141117</startdate><enddate>20141117</enddate><creator>Oelze, Matthias</creator><creator>Kröller-Schön, Swenja</creator><creator>Welschof, Philipp</creator><creator>Jansen, Thomas</creator><creator>Hausding, Michael</creator><creator>Mikhed, Yuliya</creator><creator>Stamm, Paul</creator><creator>Mader, Michael</creator><creator>Zinßius, Elena</creator><creator>Agdauletova, Saule</creator><creator>Gottschlich, Anna</creator><creator>Steven, Sebastian</creator><creator>Schulz, Eberhard</creator><creator>Bottari, Serge P</creator><creator>Mayoux, Eric</creator><creator>Münzel, Thomas</creator><creator>Daiber, Andreas</creator><general>Public Library of Science</general><general>Public Library of Science (PLoS)</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>IOV</scope><scope>ISR</scope><scope>3V.</scope><scope>7QG</scope><scope>7QL</scope><scope>7QO</scope><scope>7RV</scope><scope>7SN</scope><scope>7SS</scope><scope>7T5</scope><scope>7TG</scope><scope>7TM</scope><scope>7U9</scope><scope>7X2</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FD</scope><scope>8FE</scope><scope>8FG</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABJCF</scope><scope>ABUWG</scope><scope>AEUYN</scope><scope>AFKRA</scope><scope>ARAPS</scope><scope>ATCPS</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BGLVJ</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>D1I</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>KB.</scope><scope>KB0</scope><scope>KL.</scope><scope>L6V</scope><scope>LK8</scope><scope>M0K</scope><scope>M0S</scope><scope>M1P</scope><scope>M7N</scope><scope>M7P</scope><scope>M7S</scope><scope>NAPCQ</scope><scope>P5Z</scope><scope>P62</scope><scope>P64</scope><scope>PATMY</scope><scope>PDBOC</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PTHSS</scope><scope>PYCSY</scope><scope>RC3</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope></search><sort><creationdate>20141117</creationdate><title>The sodium-glucose co-transporter 2 inhibitor empagliflozin improves diabetes-induced vascular dysfunction in the streptozotocin diabetes rat model by interfering with oxidative stress and glucotoxicity</title><author>Oelze, Matthias ; Kröller-Schön, Swenja ; Welschof, Philipp ; Jansen, Thomas ; Hausding, Michael ; Mikhed, Yuliya ; Stamm, Paul ; Mader, Michael ; Zinßius, Elena ; Agdauletova, Saule ; Gottschlich, Anna ; Steven, Sebastian ; Schulz, Eberhard ; Bottari, Serge P ; Mayoux, Eric ; Münzel, Thomas ; Daiber, Andreas</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c762t-1b0cfbc8c5f4ef94b6a36e5ddc46891958451c7bd83bc9ba355b32edcfed8d423</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2014</creationdate><topic>Advanced glycosylation end products</topic><topic>Age</topic><topic>Animals</topic><topic>Antidiabetics</topic><topic>Aorta</topic><topic>Benzhydryl Compounds - administration & dosage</topic><topic>Benzhydryl Compounds - pharmacology</topic><topic>Blood</topic><topic>Blood glucose</topic><topic>Blood Glucose - drug effects</topic><topic>Blood vessels</topic><topic>Cardiology</topic><topic>Chemiluminescence</topic><topic>Cytokines - genetics</topic><topic>Cytokines - metabolism</topic><topic>Dehydrogenases</topic><topic>Diabetes</topic><topic>Diabetes Complications - drug therapy</topic><topic>Diabetes Complications - metabolism</topic><topic>Diabetes mellitus</topic><topic>Diabetes Mellitus, Experimental</topic><topic>Diabetes therapy</topic><topic>Diabetic Angiopathies - drug therapy</topic><topic>Diabetic Angiopathies - metabolism</topic><topic>Diabetic neuropathy</topic><topic>Drinking water</topic><topic>Drugs</topic><topic>Enzyme-linked immunosorbent assay</topic><topic>Excretion</topic><topic>Fluorescence</topic><topic>Gene Expression</topic><topic>Glucose</topic><topic>Glucose - metabolism</topic><topic>Glucose transporter</topic><topic>Glucosides - administration & dosage</topic><topic>Glucosides - pharmacology</topic><topic>Glycosylation</topic><topic>Health aspects</topic><topic>Hemodynamics - drug effects</topic><topic>Hyperglycemia</topic><topic>Hypoglycemic agents</topic><topic>Inflammation</topic><topic>Inflammation Mediators - metabolism</topic><topic>Inhibitors</topic><topic>Injection</topic><topic>Insulin</topic><topic>Insulin - blood</topic><topic>Insulin - metabolism</topic><topic>Intravenous administration</topic><topic>Isometric</topic><topic>Laboratory animals</topic><topic>Male</topic><topic>Medicine and Health Sciences</topic><topic>Oxidation</topic><topic>Oxidative stress</topic><topic>Oxidative Stress - drug effects</topic><topic>Pancreas</topic><topic>Polymerase chain reaction</topic><topic>Rats</topic><topic>Receptor for Advanced Glycation End Products</topic><topic>Receptors, Immunologic - metabolism</topic><topic>RNA</topic><topic>RNA, Messenger - genetics</topic><topic>Rodents</topic><topic>Signal Transduction</topic><topic>Signaling</topic><topic>Sodium</topic><topic>Sodium-Glucose Transporter 2 - antagonists & inhibitors</topic><topic>Staining</topic><topic>Streptozocin</topic><topic>Streptozocin - adverse effects</topic><topic>Studies</topic><topic>Type 1 diabetes</topic><topic>Type 2 diabetes</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Oelze, Matthias</creatorcontrib><creatorcontrib>Kröller-Schön, Swenja</creatorcontrib><creatorcontrib>Welschof, Philipp</creatorcontrib><creatorcontrib>Jansen, Thomas</creatorcontrib><creatorcontrib>Hausding, Michael</creatorcontrib><creatorcontrib>Mikhed, Yuliya</creatorcontrib><creatorcontrib>Stamm, Paul</creatorcontrib><creatorcontrib>Mader, Michael</creatorcontrib><creatorcontrib>Zinßius, Elena</creatorcontrib><creatorcontrib>Agdauletova, Saule</creatorcontrib><creatorcontrib>Gottschlich, Anna</creatorcontrib><creatorcontrib>Steven, Sebastian</creatorcontrib><creatorcontrib>Schulz, Eberhard</creatorcontrib><creatorcontrib>Bottari, Serge P</creatorcontrib><creatorcontrib>Mayoux, Eric</creatorcontrib><creatorcontrib>Münzel, Thomas</creatorcontrib><creatorcontrib>Daiber, Andreas</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Gale In Context: Opposing Viewpoints</collection><collection>Gale In Context: Science</collection><collection>ProQuest Central (Corporate)</collection><collection>Animal Behavior Abstracts</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Biotechnology Research Abstracts</collection><collection>Nursing & Allied Health Database</collection><collection>Ecology Abstracts</collection><collection>Entomology Abstracts (Full archive)</collection><collection>Immunology Abstracts</collection><collection>Meteorological & Geoastrophysical Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Agricultural Science Collection</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Technology Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Materials Science & Engineering Collection</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest One Sustainability</collection><collection>ProQuest Central UK/Ireland</collection><collection>Advanced Technologies & Aerospace Collection</collection><collection>Agricultural & Environmental Science Collection</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Technology Collection</collection><collection>Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Materials Science Collection</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Materials Science Database</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Meteorological & Geoastrophysical Abstracts - Academic</collection><collection>ProQuest Engineering Collection</collection><collection>ProQuest Biological Science Collection</collection><collection>Agricultural Science Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biological Science Database</collection><collection>Engineering Database</collection><collection>Nursing & Allied Health Premium</collection><collection>Advanced Technologies & Aerospace Database</collection><collection>ProQuest Advanced Technologies & Aerospace Collection</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Environmental Science Database</collection><collection>Materials Science Collection</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>Engineering Collection</collection><collection>Environmental Science Collection</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>PloS one</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Oelze, Matthias</au><au>Kröller-Schön, Swenja</au><au>Welschof, Philipp</au><au>Jansen, Thomas</au><au>Hausding, Michael</au><au>Mikhed, Yuliya</au><au>Stamm, Paul</au><au>Mader, Michael</au><au>Zinßius, Elena</au><au>Agdauletova, Saule</au><au>Gottschlich, Anna</au><au>Steven, Sebastian</au><au>Schulz, Eberhard</au><au>Bottari, Serge P</au><au>Mayoux, Eric</au><au>Münzel, Thomas</au><au>Daiber, Andreas</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The sodium-glucose co-transporter 2 inhibitor empagliflozin improves diabetes-induced vascular dysfunction in the streptozotocin diabetes rat model by interfering with oxidative stress and glucotoxicity</atitle><jtitle>PloS one</jtitle><addtitle>PLoS One</addtitle><date>2014-11-17</date><risdate>2014</risdate><volume>9</volume><issue>11</issue><spage>e112394</spage><epage>e112394</epage><pages>e112394-e112394</pages><issn>1932-6203</issn><eissn>1932-6203</eissn><abstract>In diabetes, vascular dysfunction is characterized by impaired endothelial function due to increased oxidative stress. Empagliflozin, as a selective sodium-glucose co-transporter 2 inhibitor (SGLT2i), offers a novel approach for the treatment of type 2 diabetes by enhancing urinary glucose excretion. The aim of the present study was to test whether treatment with empagliflozin improves endothelial dysfunction in type I diabetic rats via reduction of glucotoxicity and associated vascular oxidative stress.
Type I diabetes in Wistar rats was induced by an intravenous injection of streptozotocin (60 mg/kg). One week after injection empagliflozin (10 and 30 mg/kg/d) was administered via drinking water for 7 weeks. Vascular function was assessed by isometric tension recording, oxidative stress parameters by chemiluminescence and fluorescence techniques, protein expression by Western blot, mRNA expression by RT-PCR, and islet function by insulin ELISA in serum and immunohistochemical staining of pancreatic tissue. Advanced glycation end products (AGE) signaling was assessed by dot blot analysis and mRNA expression of the AGE-receptor (RAGE).
Treatment with empagliflozin reduced blood glucose levels, normalized endothelial function (aortic rings) and reduced oxidative stress in aortic vessels (dihydroethidium staining) and in blood (phorbol ester/zymosan A-stimulated chemiluminescence) of diabetic rats. Additionally, the pro-inflammatory phenotype and glucotoxicity (AGE/RAGE signaling) in diabetic animals was reversed by SGLT2i therapy.
Empagliflozin improves hyperglycemia and prevents the development of endothelial dysfunction, reduces oxidative stress and improves the metabolic situation in type 1 diabetic rats. These preclinical observations illustrate the therapeutic potential of this new class of antidiabetic drugs.</abstract><cop>United States</cop><pub>Public Library of Science</pub><pmid>25402275</pmid><doi>10.1371/journal.pone.0112394</doi><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1932-6203 |
| ispartof | PloS one, 2014-11, Vol.9 (11), p.e112394-e112394 |
| issn | 1932-6203 1932-6203 |
| language | eng |
| recordid | cdi_plos_journals_1625577213 |
| source | MEDLINE; DOAJ Directory of Open Access Journals; EZB-FREE-00999 freely available EZB journals; PubMed Central; Free Full-Text Journals in Chemistry; Public Library of Science (PLoS) |
| subjects | Advanced glycosylation end products Age Animals Antidiabetics Aorta Benzhydryl Compounds - administration & dosage Benzhydryl Compounds - pharmacology Blood Blood glucose Blood Glucose - drug effects Blood vessels Cardiology Chemiluminescence Cytokines - genetics Cytokines - metabolism Dehydrogenases Diabetes Diabetes Complications - drug therapy Diabetes Complications - metabolism Diabetes mellitus Diabetes Mellitus, Experimental Diabetes therapy Diabetic Angiopathies - drug therapy Diabetic Angiopathies - metabolism Diabetic neuropathy Drinking water Drugs Enzyme-linked immunosorbent assay Excretion Fluorescence Gene Expression Glucose Glucose - metabolism Glucose transporter Glucosides - administration & dosage Glucosides - pharmacology Glycosylation Health aspects Hemodynamics - drug effects Hyperglycemia Hypoglycemic agents Inflammation Inflammation Mediators - metabolism Inhibitors Injection Insulin Insulin - blood Insulin - metabolism Intravenous administration Isometric Laboratory animals Male Medicine and Health Sciences Oxidation Oxidative stress Oxidative Stress - drug effects Pancreas Polymerase chain reaction Rats Receptor for Advanced Glycation End Products Receptors, Immunologic - metabolism RNA RNA, Messenger - genetics Rodents Signal Transduction Signaling Sodium Sodium-Glucose Transporter 2 - antagonists & inhibitors Staining Streptozocin Streptozocin - adverse effects Studies Type 1 diabetes Type 2 diabetes |
| title | The sodium-glucose co-transporter 2 inhibitor empagliflozin improves diabetes-induced vascular dysfunction in the streptozotocin diabetes rat model by interfering with oxidative stress and glucotoxicity |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-09T14%3A45%3A18IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_plos_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20sodium-glucose%20co-transporter%202%20inhibitor%20empagliflozin%20improves%20diabetes-induced%20vascular%20dysfunction%20in%20the%20streptozotocin%20diabetes%20rat%20model%20by%20interfering%20with%20oxidative%20stress%20and%20glucotoxicity&rft.jtitle=PloS%20one&rft.au=Oelze,%20Matthias&rft.date=2014-11-17&rft.volume=9&rft.issue=11&rft.spage=e112394&rft.epage=e112394&rft.pages=e112394-e112394&rft.issn=1932-6203&rft.eissn=1932-6203&rft_id=info:doi/10.1371/journal.pone.0112394&rft_dat=%3Cgale_plos_%3EA418424611%3C/gale_plos_%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1625577213&rft_id=info:pmid/25402275&rft_galeid=A418424611&rft_doaj_id=oai_doaj_org_article_89298fb08472410b8081d15236c79a94&rfr_iscdi=true |